The week in pharma: action, reaction and insight – week to January 28, 2022

30 January 2022

By Barbara Obstoj-Cardwell. Editor

With the fourth-quarter financial results season starting, Johnson & Johnson, as ever, was the first big pharma to release figures on Tuesday, and these beat expectations. US biotech Incyte last Tuesday announced a clinical setback for its parsaclisib trial and decision to opt out of continued development of MCLA-145 with Mersus. Troubled US biotech Biogen has entered a deal to sell its nearly 50% stake in Samsung Bioepis, the biosimilars joint venture Samsung BioLogics, for $2.3 billion. TG Therapeutics suffered a setback with the US Food and Drug Administration putting a partial clinical hold on its study of leukemia candidate Ukoniq, but the news was more to do with how it slipped out.

J&J looks to be bolder on deals

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK